Compare GE Aerospace (GE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Vertex Pharmaceuticals Incorporated — how do they compare? GE Aerospace trades at $308.2 (market cap $317.10B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: GE Aerospace is far larger — about 2.5× Vertex Pharmaceuticals Incorporated's market cap, and GE Aerospace pays a 0.62% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GE | VRTX | |
|---|---|---|
Market Cap | $317.10B | $127.55B |
Volume | 6,320,106 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $381.22 | $557.96 |
52-Week Low | $273.25 | $407.37 |
Typical Hold Time | 111 Days | 120 Days |
Enterprise Value | $326.91B | $121.68B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $303.62, down 1.86% amid broader market weakness, with technical indicators showing bearish momentum despite strong fundamentals. The company has consistently beaten earnings expectations with Q2 2026 EPS of $2.02 exceeding estimates, while revenue growth accelerated to $45.86 billion in 2025. Recent news highlights GE's $12 billion acquisition of Consolidated Precision Products to address supply chain constraints in jet engine components.
The stock presents a compelling value opportunity with a 35% upside to the consensus price target of $409.60, supported by 24 buy ratings and no sell recommendations. However, high valuation multiples and integration risks from the CPP acquisition warrant caution. Strong free cash flow generation and shareholder returns through dividends and buybacks provide downside protection.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
